Sponsored Link: This Investment Must Pay You $2,250 Next Wednesday

Access Research Group


Have you ever wondered how some hedge fund managers continue to rack up huge gains year after year while most individual investors have to settle for little more than average returns?

Like many things in life, you get what you pay for.

This is certainly something that America’s top hedge fund managers know - and is exactly why they paid millions of dollars per year for the first-class investment analysis and thorough research of Marc Lichtenfeld’s former firm.

Today, Marc is Director of Research for Access - an “institutional-style” healthcare research and investing service.

Unlike most institutional research, Access is completely independent and unbiased.  Differing from the big investment houses, Access has absolutely no financial relationship to any of the companies recommended, nor does it own the shares personally.

The only way we make money is if you’re happy with your membership. And with that membership, you’ll be treated just like a hedge fund client.

The Door To Success Is Right Here… And You’ve Got The Key

When you subscribe to Access, you get your money’s worth and more, unlocking benefits that aid you in navigating the stock market.

  • Through Marc’s proprietary F.I.R.S.T. research methodology, he digs deep into the prospects of the companies on his shortlist. Unless a company passes all five phases, he doesn’t recommend it. Period.
  • If a company passes those tests, Marc issues an easy-to-read report, with the full story on its developments, highlights, earnings estimates, and the catalysts and reasons for why it’s set to make a move.

And here’s the best part…

The team then arranges an exclusive, private conference call with the management of the respective company, along with an independent expert.

After that, you can expect weekly updates on all the companies in the portfolio, any breaking news, updates on their competition, regulatory environment and market conditions. We show you what it all means for the stock, as well as when to add to a position or take profits off the table.

In all, you’ll receive six to eight recommendations per year on small-cap and micro-cap stocks, mainly in healthcare and biotech fields.

Why only this number when most other newsletters offer at least one every month?

The reason is simple. Access is not a newsletter; it is a research product. The type of research Marc and his team conducts doesn’t adhere to a deadline. If they need to hold off on a recommendation until they speak with a key player in the industry, or verify a vital piece of data, they will.

It doesn’t matter if it’s the first, fifteenth or last day of the month.  No report will be issued until they are completely comfortable that the opportunity not only has the potential, but the likelihood for 200-300% gains, or more.

In short, this means that you get quality. And in the investment world-as well as any other-that’s what really counts.

But Doesn’t Small-Cap Mean Big Risk?

Why take a risk on stocks that just may do well? Isn’t that risky?

Not really, since Marc doesn’t get involved unless he believes there is the strong potential for the stocks to at least triple in value over the next three years.

And in the early stages of developing innovative and game-changing technologies, medicines and businesses, these companies will have significant ownership by insiders and savvy investors, who boast stellar long-term track records. In addition, the potential for large profits is much higher before a company’s developments make mainstream news.

The Guy Behind The “Access” Door

Without doubt, Marc possesses strong expertise in the healthcare and biotech area.

He started out as a trader at Carlin Equities, and then moved onto contrarian Avalon Research Group as a Senior Analyst.

He also obtained his NASD Series 86 & 87 licenses (required for all sell-side analysts). At Weiss Research, he co-managed the Real Wealth Portfolio and beat the S&P 500 by 17% over a six month period.

Marc joined the team following a successful spell as Senior Columnist at TheStreet.com, where he broke several major stories on biotech companies. He’s a contrarian investor by nature and loves to shoot holes in conventional thinking and take profits where nobody else is looking. His investment approach blends thorough fundamental research with the timing tools of technical analysis.

And now, he’s giving you “access” to some of his top picks.

Institutional-Style Research For A Fraction Of The Price

Access is one of the very few research products that we know of that provides individual investors with the same level of research previously reserved for hedge funds, mutual funds and pension funds.

Once only available to portfolio managers with at least tens or hundreds of millions of dollars, you’ll receive the same research, treatment and service as if you managed a $1 billion portfolio for the world’s wealthiest investors.

And really, you can’t beat that offer.

Here are the full details on Marc Lichtenfeld and Access.

Here’s What People Are Saying About Access

“I can’t help but notice that each of your recommendations has burst from the gate.”

Alan H.

“Marc, although I’ve only been in this service for a month or so, I have to say I really like your approach. I think it’s really good that you give us updates regularly. It keeps the relationship current, if you will. With all of these premium-type investor services, it’s hard to tell exactly how much time someone is putting into their recommendations except by how much they communicate with you. Some services just say ‘buy this… period.’  I much prefer a nuanced discussion of the risks and rewards of a particular investment.”

Jeremy

“I guess you could say I’m a Mt Vernon type of guy. Now I am anxiously looking forward to the next [pick]!! You can bet I’ll buy it. Some of [your picks] have already doubled for me and I am on the house’s money. Keep up the great work.”

Rich R. (Lifetime Subscriber)

“Marc, I just wanted to let you know what a great job you did as the host of our telephone conference on Monday 4/7. I look forward to receiving additional Access reports from you in the future.  Your research is top notch and I believe well worth the price.”

Barry K. Annandale, NJ